The observational study on efficacy of oral anticoagulants for cognitive dysfunctions of the patients after cerebral infarction in super-aged society

The observational study on efficacy of oral anticoagulants for cognitive dysfunctions of the patients after cerebral infarction in super-aged society - The study on NOAC for prevention of dementia after stroke

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000026912

Enrollment

160

Registered

2017-07-01

Start date

2017-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-valvular atrial fibrillation (NVAF)

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) non-valvular atrial fibrillation 2) the use of oral anticoagulants (warfarin and NOACs) 3) CDR 0-0.5 and MMSE 24-30 4) informed consent is obtained 5) the age over 49 and under 100 year-old 6) the patients after cerebral infarction (over 6 months after the onset)

Exclusion criteria

Exclusion criteria: 1) valvular atrial fibrillation 2) CDR>0.5 or MMSE<24 3) the patients after cerebral infarction (under 6 months after the onset) 4) Parkinson disease, Huntington disease, normal pressure hydrocephalus, brain tumor, progressive supranuclear palsy, corticobasal degeneration, multiple system atrophy, epilepsy, subdural hematoma, encephalitis/meningitis, multiple sclerosis, or cognitive decline by head trauma 5) depression, schizophrenia, alcoholism, drug dependence, or other critical disease 6) deficiency of vitamin B1, B12, or folic acid, syphilis, or hypothyroidism 7) difficult to perform the neuropsychological examination 8) other inappropriate state assessed by the researchers

Design outcomes

Primary

Measure	Time frame
the change of MMSE (mini-mental state examination) score between baseline and after 2 years of the registration	—

Secondary

Measure	Time frame
1) occurrences of death from any cause, dementia, stroke, and cardiovascular events 2) the change of CDR score 3) the change of MoCA score 4) occurrences of hemorrhagic events 5) occurrences of ischemic events	—

Countries

Japan

Contacts

Public ContactYumiko Nakano

Okayama University Hospital Department of Neurology

yumikonakano@okayama-u.ac.jp086-235-7365

Outcome results